

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 7/19/02

Signature:

(Anna P. Lucey)

#5
Docket No.: BURF-P02-006
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614
RECEIVED

JUL 26 2002

In re Patent Application of:
Fallon et al.

Application No.: 10/081736

Group Art Unit: 1614

TECH CENTER 1600/2900

Filed: February 20, 2002

Examiner: Not Yet Assigned

For: BIGLYCAN AND RELATED
THERAPEUTICS AND METHODS OF USE

COPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.


In accordance with C.F.R. 1.98(d), applicants respectfully submit that no copy of any patent, publication, or other information listed on the enclosed Form PTO-1449 is needed because the citations were made in prior application U.S.S.N. 09/715,836 filed November 17, 2000 which is relied upon in this application for an earlier filing date under 35 U.S.C. 120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Dated:


Respectfully submitted,

By 
Agnes S. Lee

Registration No.: 46,862
ROPES & GRAY
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys for Applicant

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Docket Number (Optional) BURF-P02-006		Application Number 10/081,736	
			Applicant Fallon et al.			Group Art Unit 1614
			Filing Date February 20, 2000			
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,340,934	8/23/94	Termine et al.		RECEIVED JUL 26 2002
	AB	5,705,609	1/6/98	Ruoslahti et al.		
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
	AC	EP 0686397 A2	4/29/95	EP		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.)						
	AD	Bianco, P. et al. Expression and Localization of the Two Small Proteoglycans, Biglycan and Decorin, in Developing Human Skeletal and Non-Skeletal Tissues. <i>J. Histochem. Cytochem</i> 38, 1549-1563 (Nov. 1990).				
	AE	Bowe, M. A. et al. The Small Lucine-rich Repeat Proteoglycan Biglycan Binds to Dystroglycan and is Unregulated in Dystrophic Muscle. <i>J. Cell. Biol.</i> 148, 801-810 (2000).				
	AF	Chan, Yiu-mo et al. Molecular Organization of Sarcoglycan Complex in Mouse Myotubes in Culture. <i>J. Cell Bio.</i> 143, 2033-2044 (28 December 1998).				
	AG	Coral-Vasquez, R. et al. Disruption of the Sarcoglycan-Sarcospan Complex in Vascular Smooth Muscle: A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy. <i>Cell</i> 98, 465-74 (1999).				
	AH	Crosbie, Rachelle H. et al. Membrane Targeting and Stabilization of Sarcospan is Mediated by the Sarcoglycan Subcomplex. <i>J. Cell. Biol.</i> 145, 159-165 (5 April 1999).				
	AI	Ervasti, James M. & Campbell, Kevin P. A Role for the Dystrophin-Glycoprotein Complex as a Transmembrane Linker between Laminin and Actin. <i>J. Cell Biol.</i> 122, 809-823 (August 1993).				
	AJ	Ferri, R. T. et al. A Role for Biglycan in Agrin-Induced Postsynaptic Differentiation. <i>Society for Neuroscience Abstracts</i> 26 (2000) [ABSTRACT ONLY].				
	AK	Fisher, L. W. et al. Deduced Protein Sequence of Bone Small Proteoglycan I (Biglycan) Shows Homology with Proteoglycan II (Decorin) and Several Nonconnective Tissue Proteins in a Variety of Species. <i>J. Biol. Chem.</i> 264, 4571 (1989).				
	AL	Gee, Stephen H. et al. Dystroglycan-a, a Dystrophin-Associated Glycoprotein, is a Functional Agrin Receptor. <i>Cell</i> 77, 675-686 (3 June 1994).				
	AM	Hoch, Werner. Formation of the Neuromuscular Junction: Agrin and its unusual receptors. <i>Eur. J. Biochem.</i> 265, 1-10 (1999).				
	AN	Hocking, A. M. et al. Eukaryotic Expression of Recombinant Biglycan. <i>Am. Soc. For Biochem. & Mol. Biol.</i> 27, 19571-77 (1996).				

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION***(Use several sheets if necessary)*Docket Number (Optional)
BURF-P02-006Application Number
10/081,736Applicant
Fallon et al.Filing Date
February 20, 2000Group Art Unit
1614

AO	Holt, Kathleen H. et al. Functional Rescue of the Sarcoglycan Complex in BIO 14.6 Hamster Using S-Sarcoglycan Gene Transfer. <i>Mol. Cell</i> 1, 841-848 (May 1998).
AP	Ibraghimov-Besirovanaya et al. Human Dystroglycan: Skeletal Muscle cDNA, Genomic Structure, Origin of Tissue Specific Isoforms and Chromosomal Localization. <i>Hum. Mol. Genet.</i> 2, 1651-1657 (1993).
AQ	Iozzo, R. Matrix Proteoglycans: From Molecular Design to Cellular Function. <i>Ann. Rev. Biochem.</i> 67, 609-652 (1998).
AR	Jarvelainen, Hannu T. et al. Differential Expression of Small Chondroitin/Dermatan Sulfate Proteoglycans, PG-I/Biglycan and PG-II/Decorin, by Vascular Smooth Muscle and Endothelial Cells in Culture. <i>J. Biol. Chem.</i> 266, 23274-23281 (5 December 1991).
AS	Junghans, Ulrich et al. Purification of a Meningeal Cell-derived Chondroitin Sulphate Proteoglycan with Neurotrophic Activity for Brain Neurons and its Identification as Biglycan. <i>Euro. J. Neurosci.</i> 7, 2341-2350 (1995).
AT	Khurana, T. S. et al. Interaction of ARIA, a Neuregulin, with the Dystroglycan / Sarcoglycan Complex in Skeletal Muscle. <i>Mol. Cell. Biol.</i> 7, 314 (1996).
AU	Krishnan, P. et al. Distinct Secondary Structures of the Leucine-rich Repeat Proteoglycans Decorin and Biglycan. <i>J. Biol. Chem.</i> 274, 10945-50 (1999).
AV	Sakamoto, Aiji et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, S-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. <i>PNAS</i> 94, 13873-13878 (December 1997).
AW	Tomoyasu, Hiroshi et al. Identification of haemopoietic biglycan in hyperplastic thymus associated with myasthenia gravis. <i>J. Neuroimmunology</i> 89, 59-63 (1998).
AX	Winder, Steven J. The complexities of dystroglycan. <i>Trends in Biochem. Sci.</i> 26, 118-124 (2001).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVEDCOPY OF PAPERS
ORIGINALLY FILED

JUL 26 2002

TECH CENTER 1500